Is daprodustat a treatment drug for renal anemia?

Daprodustat (Daprodustat) is a treatment drug for chronic kidney disease-related anemia (CKD anemia). It is a type of HIF-PHI oral drug that has received widespread attention around the world in recent years. Its core mechanism of action is to help patients restore normal red blood cell levels and improve anemia symptoms by affecting the erythropoiesis pathway in the body.

Renal anemia is essentially caused by chronic kidney disease, which reduces the ability of the kidneys to synthesize endogenous erythropoietin (EPO), causing obstruction of red blood cell production. In traditional treatment, injectable ESAs (erythropoietin drugs) are mostly relied on to maintain hemoglobin levels, but their limitations become apparent during long-term use. Daprostat provides a new treatment method. It inhibits the HIF-PHD enzyme in the body to continuously activate HIF signaling, thereby promoting the body's natural production of appropriate amounts of EPO. It also improves iron absorption, iron transport and iron utilization efficiency, making the approach to correct anemia more consistent with physiological mechanisms.

Based on the data, daprostat was initially approved for use in patients with chronic kidney disease anemia who have been receiving dialysis for at least four months. Such patients often have long-term stable anemia and require ongoing intervention to maintain hemoglobin levels. One of the major advantages of dapostat is the oral administration mode, which eliminates the need for patients to rely on centralized injection treatment in dialysis centers, improving convenience and reducing injection-related risks. Secondly, oral medication can produce relatively smooth fluctuations in EPO levels in the body, which is consistent with natural rhythms and helps reduce the risk of extreme hemoglobin elevations.

In addition to helping the body increase endogenous EPO levels Daprostat can also positively regulate key links in iron metabolism, including reducing the level of hepcidin in the serum, thereby improving iron absorption and increasing iron utilization. This is particularly important for patients with long-term dialysis and obvious iron utilization disorders. Due to these comprehensive mechanisms, daprostat not only improves anemia, but also reduces patients' need for blood transfusions, which is of practical significance in avoiding the immune burden caused by blood transfusions.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat